Last reviewed · How we verify
Deep venous thrombosis
Approved treatments
- Xarelto · University Hospital, Montpellier
- nadroparin · Onze Lieve Vrouwe Gasthuis
- Fragmin · Pfizer
Fragmin works by binding to and activating antithrombin, which inhibits the coagulation cascade. - Arixtra · Mylan Ireland Ltd
Arixtra works by blocking the action of factor Xa, a protein involved in blood clotting. - Lovenox (Preservative Free) · Sanofi
Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting. - Heparin Sodium In Plastic Container · Merck & Co.
Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots. - Xarelto · Johnson & Johnson
Selective FXa inhibitor that decreases thrombin generation without requiring cofactors. - Heparin Sodium In Plastic Container · Fresenius Kabi
Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa. - Coumadin · Generic (originally Wisconsin Alumni Research Foundation)
Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis. - Fraxiparin
- Dabigatran Etexilate · Boehringer Ingelheim
Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process. - Dabigatran Etexilate · Boehringer Ingelheim
Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process. - Arixtra · LifeBridge Health
- Lovenox · University of Monastir
- Enoxaparin · Dana-Farber Cancer Institute
- Fraxiparine · Leiden University Medical Center
Clinical guidelines
- FDA label — 1L
Prophylaxis and treatment of venous thrombosis - FDA label — 1L
Prophylaxis and treatment of venous thrombosis - FDA label — 1L
Prophylaxis and treatment of venous thrombosis - FDA label — 1L
Prophylaxis and treatment of venous thrombosis - FDA label — 1L
Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Deep venous thrombosis patent landscape — cliff calendar, originator estates, attackable patents
- Deep venous thrombosis treatment landscape brief
- Deep venous thrombosis treatment updates RSS
Frequently asked questions about Deep venous thrombosis
What drugs treat Deep venous thrombosis?
Tracked treatments include Xarelto, nadroparin, Fragmin, Arixtra, Lovenox (Preservative Free), Heparin Sodium In Plastic Container, Coumadin, Fraxiparin.
What is the treatment for Deep venous thrombosis?
Standard treatment for Deep venous thrombosis includes Xarelto, nadroparin, Fragmin, Arixtra, Lovenox (Preservative Free). See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Deep venous thrombosis?
FDA label publishes guidelines for Deep venous thrombosis. 5 guideline references tracked.
Related
- Treatment landscape: Deep venous thrombosis patent cliff · Deep venous thrombosis CI report
- Treatment: Xarelto · University Hospital, Montpellier
- Treatment: nadroparin · Onze Lieve Vrouwe Gasthuis
- Treatment: Fragmin · Pfizer
- Treatment: Arixtra · Mylan Ireland Ltd
- Treatment: Lovenox (Preservative Free) · Sanofi
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing